AP2184A - Benzimidazolone compounds having 5-HT4 receptor agonistic activity. - Google Patents

Benzimidazolone compounds having 5-HT4 receptor agonistic activity.

Info

Publication number
AP2184A
AP2184A AP2006003536A AP2006003536A AP2184A AP 2184 A AP2184 A AP 2184A AP 2006003536 A AP2006003536 A AP 2006003536A AP 2006003536 A AP2006003536 A AP 2006003536A AP 2184 A AP2184 A AP 2184A
Authority
AP
ARIPO
Prior art keywords
agonistic activity
receptor agonistic
benzimidazolone compounds
benzimidazolone
compounds
Prior art date
Application number
AP2006003536A
Other languages
English (en)
Other versions
AP2006003536A0 (en
Inventor
Satoru Iguchi
Yasuhiro Katsu
Takashi Kojima
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP2006003536A0 publication Critical patent/AP2006003536A0/xx
Application granted granted Critical
Publication of AP2184A publication Critical patent/AP2184A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Manufacturing & Machinery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Ceramic Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2006003536A 2003-09-03 2004-08-20 Benzimidazolone compounds having 5-HT4 receptor agonistic activity. AP2184A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50014403P 2003-09-03 2003-09-03
PCT/IB2004/002741 WO2005021539A1 (fr) 2003-09-03 2004-08-20 Composes de benzimidazolone a activite d'agonistes du recepteur 5-ht4

Publications (2)

Publication Number Publication Date
AP2006003536A0 AP2006003536A0 (en) 2006-04-30
AP2184A true AP2184A (en) 2010-12-02

Family

ID=34272920

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003536A AP2184A (en) 2003-09-03 2004-08-20 Benzimidazolone compounds having 5-HT4 receptor agonistic activity.

Country Status (40)

Country Link
US (2) US7776885B2 (fr)
EP (1) EP1664036B1 (fr)
JP (1) JP3983269B1 (fr)
KR (1) KR100738784B1 (fr)
CN (1) CN100482659C (fr)
AP (1) AP2184A (fr)
AR (1) AR045552A1 (fr)
AT (1) ATE539077T1 (fr)
AU (1) AU2004268840B9 (fr)
BR (1) BRPI0414105B8 (fr)
CA (1) CA2537127C (fr)
CR (1) CR8267A (fr)
CY (1) CY1112321T1 (fr)
DK (1) DK1664036T3 (fr)
EA (1) EA009457B1 (fr)
EC (1) ECSP066407A (fr)
ES (1) ES2377484T3 (fr)
GE (1) GEP20084527B (fr)
GT (1) GT200400174A (fr)
HK (1) HK1093338A1 (fr)
HR (1) HRP20120077T1 (fr)
IL (3) IL173705A (fr)
IS (1) IS8289A (fr)
MA (1) MA28021A1 (fr)
MX (1) MXPA06002550A (fr)
NL (1) NL1026959C2 (fr)
NO (1) NO20061519L (fr)
OA (1) OA13248A (fr)
PA (1) PA8610601A1 (fr)
PE (1) PE20050874A1 (fr)
PL (1) PL1664036T3 (fr)
PT (1) PT1664036E (fr)
RS (1) RS20060145A (fr)
SI (1) SI1664036T1 (fr)
TN (1) TNSN06073A1 (fr)
TW (1) TW200510332A (fr)
UA (1) UA86204C2 (fr)
UY (1) UY28496A1 (fr)
WO (1) WO2005021539A1 (fr)
ZA (1) ZA200601324B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
KR100738784B1 (ko) * 2003-09-03 2007-07-12 화이자 인코포레이티드 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
MXPA06014486A (es) 2004-06-15 2007-03-01 Pfizer Derivados de acido carboxilico de bencimidazolona.
ES2327142T3 (es) 2004-11-05 2009-10-26 Theravance, Inc. Compuestos de quinolinona-carboxamida.
WO2006052640A1 (fr) 2004-11-05 2006-05-18 Theravance, Inc. Composés antagonistes du récepteur 5-ht4
NZ555180A (en) 2004-12-22 2010-09-30 Theravance Inc Indazole-carboxamide compounds useful as 5-HT4 receptor agonists
AP2007004067A0 (en) 2005-02-22 2007-08-31 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
NZ560828A (en) 2005-03-02 2011-01-28 Theravance Inc Quinolinone compounds as 5-HT4 receptor agonists
EP1861377B1 (fr) * 2005-03-15 2010-12-29 Pfizer, Inc. Derives de benzimidazolone en tant que ligands de recepteur cb2
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
ATE495171T1 (de) * 2005-06-07 2011-01-15 Theravance Inc Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
EA016286B1 (ru) * 2005-09-30 2012-03-30 Глэксо Груп Лимитед Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
ES2391107T3 (es) 2005-09-30 2012-11-21 Glaxo Group Limited Compuestos que tienen actividad en el receptor M1 y sus usos en medicina
US8288413B2 (en) * 2005-09-30 2012-10-16 Glaxo Group Limited Benzimidazolones which have activity at M1 receptor
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
EP1984027B1 (fr) * 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Composition pharmaceutique comprenant un composé bicyclique et procédé pour stabiliser ce composé bicyclique
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
US20080318964A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched eszopiclone
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
US8642772B2 (en) * 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
WO2011099305A1 (fr) * 2010-02-12 2011-08-18 Raqualia Pharma Inc. Agonistes du récepteur 5-ht4 pour le traitement de la démence
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US20120143119A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of Serotonin Receptor Antagonists By Microinjection Systems
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
WO2017093890A1 (fr) * 2015-11-30 2017-06-08 Piramal Enterprises Limited Formulation de comprimé à base de clobazam et son procédé de préparation
UY39479A (es) * 2020-10-23 2021-11-30 Hk Inno N Corp Comprimido de desintegración oral que comprende compuesto derivado de benzimidazol y procedimiento de preparación del mismo

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522914A1 (fr) * 1991-06-27 1993-01-13 Synthelabo Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique
WO2000037461A1 (fr) * 1998-12-22 2000-06-29 Janssen Pharmaceutica N.V. 4-(aminomethyl)-piperidine benzamides permettant de traiter les troubles gastro-intestinaux
WO2002053568A1 (fr) * 2000-12-28 2002-07-11 Mochida Pharmaceutical Co., Ltd. Inhibiteurs de la biosynthese du cholesterol contenant comme principe actif des composes spiro tricycliques

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US63716A (en) * 1867-04-09 Improved cheery stoner
US3945953A (en) * 1972-04-21 1976-03-23 Ciba-Geigy Corporation ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use
CH566987A5 (fr) * 1972-04-21 1975-09-30 Ciba Geigy Ag
DE3336024A1 (de) * 1983-10-04 1985-04-18 Boehringer Ingelheim KG, 6507 Ingelheim 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
US5223511A (en) 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9204565D0 (en) * 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
US5300512A (en) 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
WO1994010174A1 (fr) 1992-11-05 1994-05-11 Smithkline Beecham Plc Derives de piperidine utiles comme antagonistes de recepteur de 5-ht4
TW252206B (fr) * 1993-09-01 1995-07-21 Philips Electronics Nv
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ATE266636T1 (de) 1997-09-09 2004-05-15 Bristol Myers Squibb Pharma Co Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren
US6069152A (en) 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US6420410B1 (en) 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
KR100738784B1 (ko) * 2003-09-03 2007-07-12 화이자 인코포레이티드 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
MXPA06014486A (es) 2004-06-15 2007-03-01 Pfizer Derivados de acido carboxilico de bencimidazolona.
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0522914A1 (fr) * 1991-06-27 1993-01-13 Synthelabo Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique
WO2000037461A1 (fr) * 1998-12-22 2000-06-29 Janssen Pharmaceutica N.V. 4-(aminomethyl)-piperidine benzamides permettant de traiter les troubles gastro-intestinaux
WO2002053568A1 (fr) * 2000-12-28 2002-07-11 Mochida Pharmaceutical Co., Ltd. Inhibiteurs de la biosynthese du cholesterol contenant comme principe actif des composes spiro tricycliques

Also Published As

Publication number Publication date
UY28496A1 (es) 2005-04-29
GT200400174A (es) 2005-05-02
CA2537127A1 (fr) 2005-03-10
US20050148573A1 (en) 2005-07-07
KR100738784B1 (ko) 2007-07-12
ATE539077T1 (de) 2012-01-15
EP1664036B1 (fr) 2011-12-28
DK1664036T3 (da) 2012-02-13
RS20060145A (en) 2008-06-05
AU2004268840A1 (en) 2005-03-10
HRP20120077T1 (hr) 2012-02-29
BRPI0414105B1 (pt) 2018-08-14
NL1026959A1 (nl) 2005-03-07
CN1845922A (zh) 2006-10-11
PA8610601A1 (es) 2005-03-28
IL205599A0 (en) 2010-11-30
BRPI0414105B8 (pt) 2021-05-25
ES2377484T3 (es) 2012-03-28
EA200600327A1 (ru) 2006-08-25
JP2007533613A (ja) 2007-11-22
PT1664036E (pt) 2012-02-16
ECSP066407A (es) 2006-09-18
IL173705A (en) 2013-04-30
AU2004268840B2 (en) 2010-09-23
BRPI0414105A (pt) 2006-11-21
IL173705A0 (en) 2006-07-05
IL205600A0 (en) 2010-11-30
PE20050874A1 (es) 2005-10-26
IS8289A (is) 2006-02-09
EP1664036A1 (fr) 2006-06-07
AR045552A1 (es) 2005-11-02
PL1664036T3 (pl) 2012-04-30
CY1112321T1 (el) 2015-12-09
MA28021A1 (fr) 2006-07-03
US20100273794A1 (en) 2010-10-28
HK1093338A1 (en) 2007-03-02
CN100482659C (zh) 2009-04-29
CA2537127C (fr) 2011-04-05
US7776885B2 (en) 2010-08-17
OA13248A (en) 2007-01-31
AP2006003536A0 (en) 2006-04-30
SI1664036T1 (sl) 2012-03-30
TNSN06073A1 (en) 2007-10-03
JP3983269B1 (ja) 2007-09-26
KR20060087540A (ko) 2006-08-02
EA009457B1 (ru) 2007-12-28
MXPA06002550A (es) 2006-06-20
CR8267A (es) 2006-11-21
GEP20084527B (en) 2008-11-10
UA86204C2 (uk) 2009-04-10
TW200510332A (en) 2005-03-16
NL1026959C2 (nl) 2006-01-23
WO2005021539A1 (fr) 2005-03-10
AU2004268840B9 (en) 2011-02-03
ZA200601324B (en) 2007-05-30
NO20061519L (no) 2006-06-01

Similar Documents

Publication Publication Date Title
AP2184A (en) Benzimidazolone compounds having 5-HT4 receptor agonistic activity.
IL160945A0 (en) Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity
HK1099019A1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
IL177059A0 (en) Indazole-carboxamide compounds as 5-ht4 receptor agonists
IL174990A0 (en) Compounds having crth2 antagonist activity
EP1559422A4 (fr) Agent de controle de la fonction recepteur
PL1687390T3 (pl) Zgazowanie katalityczne
HK1086010A1 (en) Ppar active compounds
GB0325093D0 (en) Fiberglass nonwoven catalyst
MA27306A1 (fr) Ligands des recepteurs de la melanocortine.
EP1631559A4 (fr) Antagonistes du recepteur il-8 sb /sb
IS2897B (is) Efnasambönd sem hamla gegn virkni kalkviðtaka
IL173337A0 (en) Receptor
EP1616880A4 (fr) Ligand a activite agoniste vis-a-vis d'un recepteur ayant subi une mutation
PT1558259E (pt) Derivados de ureia como antagonistas do receptor de il-8
GB0203412D0 (en) 5-HT 2B receptor antagonists
ZA200804010B (en) Carbamate compounds as 5-HT4 receptor agonists
GB0321998D0 (en) Receptor
GB0329104D0 (en) Receptor
GB0307100D0 (en) Receptor
TJ403B (en) Dibaferrol, having antimicrobe activity.
ES1052119Y (es) Maquina reactivadora de cortes de calzado.
AU149317S (en) Sanitary ware for pets
GB0204278D0 (en) Animal activity unit
GB0303272D0 (en) Animal activity unit